agree with you, and yet here we are, without enough data to establish SAFETY at the doses Dana Farber and Mayo et al will want to use. For those phase 2's.
As the board has stated ad nauseum, the purpose of Phase 1 is safety.
But we do not know if it will be safe at future doses(such as the drip you wrote about- just to take one example, not that a drip will be planned)